HRP20030382A2 - A combination comprising camptothecin and a stilbene derivative for the treatment of cancer - Google Patents
A combination comprising camptothecin and a stilbene derivative for the treatment of cancer Download PDFInfo
- Publication number
- HRP20030382A2 HRP20030382A2 HR20030382A HRP20030382A HRP20030382A2 HR P20030382 A2 HRP20030382 A2 HR P20030382A2 HR 20030382 A HR20030382 A HR 20030382A HR P20030382 A HRP20030382 A HR P20030382A HR P20030382 A2 HRP20030382 A2 HR P20030382A2
- Authority
- HR
- Croatia
- Prior art keywords
- combretastatin
- cpt
- combination
- treatment
- tumor
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title claims description 58
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title claims description 48
- 229940127093 camptothecin Drugs 0.000 title claims description 48
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title claims description 48
- 206010028980 Neoplasm Diseases 0.000 title claims description 30
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 title claims description 11
- 201000011510 cancer Diseases 0.000 title description 7
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical group C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims description 56
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 10
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 230000002195 synergetic effect Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 description 12
- 230000003000 nontoxic effect Effects 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000825 pharmaceutical preparation Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- -1 combretastatin Chemical class 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960005537 combretastatin A-4 Drugs 0.000 description 3
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24343100P | 2000-10-27 | 2000-10-27 | |
| US24558200P | 2000-11-06 | 2000-11-06 | |
| US25013800P | 2000-12-01 | 2000-12-01 | |
| PCT/EP2001/012985 WO2002034244A2 (fr) | 2000-10-27 | 2001-10-25 | Combinaison de camptothecine et d'un derive de stilbene pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20030382A2 true HRP20030382A2 (en) | 2005-04-30 |
Family
ID=27399663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030382A HRP20030382A2 (en) | 2000-10-27 | 2003-05-14 | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6562834B2 (fr) |
| EP (1) | EP1333820A2 (fr) |
| JP (1) | JP2004517821A (fr) |
| KR (1) | KR100742524B1 (fr) |
| CN (1) | CN1200712C (fr) |
| AU (2) | AU2002216029B2 (fr) |
| BG (1) | BG107806A (fr) |
| BR (1) | BR0114856A (fr) |
| CA (1) | CA2426898A1 (fr) |
| EA (1) | EA005400B1 (fr) |
| EE (1) | EE200300184A (fr) |
| HK (1) | HK1058623A1 (fr) |
| HR (1) | HRP20030382A2 (fr) |
| HU (1) | HUP0302629A3 (fr) |
| IL (1) | IL155509A0 (fr) |
| MX (1) | MXPA03002882A (fr) |
| NO (1) | NO324844B1 (fr) |
| NZ (1) | NZ524855A (fr) |
| PL (1) | PL365685A1 (fr) |
| SK (1) | SK5122003A3 (fr) |
| WO (1) | WO2002034244A2 (fr) |
| YU (1) | YU29803A (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
| CA2383259A1 (fr) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Composes synergiques |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
| TW200819409A (en) | 2006-10-19 | 2008-05-01 | Univ Taipei Medical | Z-stilbenes derivatives and the pharmaceutical composition thereof |
| CA2826034A1 (fr) | 2011-01-28 | 2012-08-02 | University Of Kentucky Research Foundation | Analogues de stilbene et procedes de traitement du cancer |
| KR20140147797A (ko) | 2011-06-27 | 2014-12-30 | 더 잭슨 래보라토리 | 암 및 자가면역 질환의 치료 방법 및 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| JPS57116015A (en) | 1981-01-09 | 1982-07-19 | Yakult Honsha Co Ltd | Antitumor agent |
| JPS57116074A (en) | 1981-01-09 | 1982-07-19 | Yakult Honsha Co Ltd | Novel camptothecin derivative and its preparation |
| US4473692A (en) | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| JPS58154582A (ja) | 1982-03-10 | 1983-09-14 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体およびその製造法 |
| JPS595188A (ja) | 1982-06-30 | 1984-01-12 | Yakult Honsha Co Ltd | １０−ヒドロキシカンプトテシンの製造法 |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US4981968A (en) | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| CA1332413C (fr) | 1987-06-25 | 1994-10-11 | Kabushiki Kaisha Yakult Honsha | Derives de la campothecine et methode de preparation |
| US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| JPH0615547B2 (ja) | 1988-01-20 | 1994-03-02 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体 |
| JP2524804B2 (ja) | 1988-03-29 | 1996-08-14 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体及びその製造法 |
| JP2524803B2 (ja) | 1988-03-29 | 1996-08-14 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体およびその製造法 |
| EP0540099B1 (fr) | 1991-10-29 | 1996-04-17 | Glaxo Wellcome Inc. | Dérivés de camptothécine solubles dans l'eau |
| TW325458B (en) * | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
| TW334418B (en) | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| GB9510716D0 (en) | 1995-05-26 | 1995-07-19 | Pharmacia Spa | Substituted camptothecin derivatives and process for their preparation |
| US5670500A (en) | 1995-05-31 | 1997-09-23 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| US5663177A (en) | 1995-05-31 | 1997-09-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| PT835258E (pt) | 1995-06-21 | 2003-02-28 | Sod Conseils Rech Applic | Novos analogos de camptotecina, processos para a sua preparacao, sua utilizacao como farmacos e composicoes farmaceuticas que os contem |
| JP3054669B2 (ja) | 1995-10-16 | 2000-06-19 | 余川商事株式会社 | 積雪落下防止装置 |
| JPH11296051A (ja) | 1998-04-08 | 1999-10-29 | Canon Inc | プロセスカートリッジ |
| NZ512171A (en) * | 1998-12-11 | 2004-07-30 | Medarex Inc | Prodrug compound comprising a therapeutic agent, an oligopeptide with a non-genetically encoded amino acid, a stabilizing group and optionally a linker group |
| GB9903404D0 (en) * | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
| WO2002056692A1 (fr) | 2000-12-22 | 2002-07-25 | Bristol-Myers Squibb Company | Procedes relatifs a la modulation de la croissance tumorale et de la metastase |
-
2001
- 2001-10-25 JP JP2002537298A patent/JP2004517821A/ja active Pending
- 2001-10-25 AU AU2002216029A patent/AU2002216029B2/en not_active Ceased
- 2001-10-25 NZ NZ524855A patent/NZ524855A/en unknown
- 2001-10-25 AU AU1602902A patent/AU1602902A/xx active Pending
- 2001-10-25 KR KR1020037005754A patent/KR100742524B1/ko not_active IP Right Cessation
- 2001-10-25 MX MXPA03002882A patent/MXPA03002882A/es not_active Application Discontinuation
- 2001-10-25 CN CNB018179800A patent/CN1200712C/zh not_active Expired - Fee Related
- 2001-10-25 BR BR0114856-7A patent/BR0114856A/pt not_active IP Right Cessation
- 2001-10-25 YU YU29803A patent/YU29803A/sh unknown
- 2001-10-25 EE EEP200300184A patent/EE200300184A/xx unknown
- 2001-10-25 PL PL01365685A patent/PL365685A1/xx not_active Application Discontinuation
- 2001-10-25 EP EP01988584A patent/EP1333820A2/fr not_active Withdrawn
- 2001-10-25 IL IL15550901A patent/IL155509A0/xx unknown
- 2001-10-25 HU HU0302629A patent/HUP0302629A3/hu unknown
- 2001-10-25 WO PCT/EP2001/012985 patent/WO2002034244A2/fr active IP Right Grant
- 2001-10-25 SK SK512-2003A patent/SK5122003A3/sk not_active Application Discontinuation
- 2001-10-25 EA EA200300516A patent/EA005400B1/ru not_active IP Right Cessation
- 2001-10-25 CA CA002426898A patent/CA2426898A1/fr not_active Abandoned
- 2001-10-26 US US09/984,043 patent/US6562834B2/en not_active Expired - Fee Related
-
2003
- 2003-04-10 NO NO20031656A patent/NO324844B1/no unknown
- 2003-05-12 BG BG107806A patent/BG107806A/bg unknown
- 2003-05-14 HR HR20030382A patent/HRP20030382A2/hr not_active Application Discontinuation
-
2004
- 2004-02-26 HK HK04101397A patent/HK1058623A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0302629A2 (hu) | 2003-11-28 |
| YU29803A (sh) | 2006-05-25 |
| HK1058623A1 (en) | 2004-05-28 |
| EA200300516A1 (ru) | 2003-08-28 |
| KR20030082544A (ko) | 2003-10-22 |
| US6562834B2 (en) | 2003-05-13 |
| EE200300184A (et) | 2003-08-15 |
| CN1200712C (zh) | 2005-05-11 |
| NZ524855A (en) | 2004-10-29 |
| NO324844B1 (no) | 2007-12-17 |
| NO20031656L (no) | 2003-04-10 |
| KR100742524B1 (ko) | 2007-08-02 |
| IL155509A0 (en) | 2003-11-23 |
| JP2004517821A (ja) | 2004-06-17 |
| AU1602902A (en) | 2002-05-06 |
| NO20031656D0 (no) | 2003-04-10 |
| AU2002216029B2 (en) | 2006-01-05 |
| MXPA03002882A (es) | 2004-12-03 |
| EA005400B1 (ru) | 2005-02-24 |
| BG107806A (bg) | 2004-06-30 |
| EP1333820A2 (fr) | 2003-08-13 |
| BR0114856A (pt) | 2004-06-15 |
| US20020115677A1 (en) | 2002-08-22 |
| WO2002034244A3 (fr) | 2003-05-30 |
| HUP0302629A3 (en) | 2005-05-30 |
| WO2002034244A2 (fr) | 2002-05-02 |
| SK5122003A3 (en) | 2003-12-02 |
| PL365685A1 (en) | 2005-01-10 |
| CN1471396A (zh) | 2004-01-28 |
| CA2426898A1 (fr) | 2002-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA008056B1 (ru) | Противораковые комбинации | |
| JP2001517250A (ja) | ナフタレンスルホン酸誘導体を含有する相乗作用抗腫瘍組成物 | |
| WO2000018393A1 (fr) | Chimiotherapie contre le cancer, dans laquelle de l'acetyldinaline combinee a de la gemcitabine, de la capecitabine ou du cisplatine sont utilises | |
| AU2010243267A1 (en) | Pentamidine combinations for treating cancer | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| KR20130137696A (ko) | 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도 | |
| EP3429614B1 (fr) | Méthode de traitement d'un cancer du sein triple négatif | |
| HRP20030734A2 (en) | A combination comprising combretastatin and anticancer agents | |
| EP1067941A1 (fr) | Composition antitumorale contenant une composition synergetique d'un derive d'anthracycline et d'un derive de campothecine | |
| HRP20030382A2 (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| EP1515750B1 (fr) | Combinaisons comprenant des epothilones, et utilisations pharmaceutiques de celles-ci | |
| AU2002216029A1 (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| KR101847252B1 (ko) | 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| JP2002505678A (ja) | 腫瘍組織を選択的に制御するための、相乗効果を有する組成物 | |
| EP2560647B1 (fr) | Polythérapie avec un inhibiteur du protéasome et un complexe de gallium | |
| US6548488B2 (en) | Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer | |
| ZA200302552B (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer. | |
| CA2516097A1 (fr) | Traitement combine comprenant un derive d'indolopyrrolocarbazole et un autre agent antitumoral | |
| EP1716852A1 (fr) | Composition comprenant de la camptothecine ou un derive de la camptothecine et un agent alkylant , destinee au traitement du cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20071003 Year of fee payment: 7 |
|
| OBST | Application withdrawn |